Overview

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2036-12-01

Target enrollment:

Participant gender:

Summary

This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progression free survival (PFS) among patients with previously untreated advanced non-small cell lung cancer.

Phase:

PHASE2

Details

Lead Sponsor:

University of California, Davis

Collaborator:

National Cancer Institute (NCI)

Treatments:

Standard of Care